UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): March 5, 2019
OXFORD IMMUNOTEC GLOBAL PLC
(Exact name of registrant as specified in its charter)
England and Wales
(State or other jurisdiction
of incorporation)
|
|
|
|
|
001-36200 |
|
98-1133710 |
|
(Commission |
|
(IRS Employer |
94C Innovation Drive, Milton Park, Abingdon OX14 4RZ, United Kingdom
(Address of principal executive offices)
Registrant’s telephone number including area code +44 (0) 1235 442780
Check appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On March 5, 2019, the Remuneration Committee of the Board of Directors of Oxford Immunotec Global PLC adjusted the salary and bonus target of the Chief Executive Officer, the bonus and equity targets of the Chief Operating Officer and the salary and equity target of the Senior Vice President, General Counsel as follows:
|
Executive Officer |
Base Salary for 2019 |
Target Bonus Percentage for 2019 |
Target Equity Award Percentage for 2019 |
|
Peter Wrighton-Smith, Ph.D. |
$520,000 |
100% |
200% |
|
Stefan Linn |
$416,000 |
70% |
150% |
|
Elizabeth M. Keiley |
$334,700 |
50% |
75% |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 8, 2019
|
|
OXFORD IMMUNOTEC GLOBAL PLC |
|
|
|
|
|
|
|
By: |
/s/ Elizabeth M. Keiley |
|
|
|
Elizabeth M. Keiley SVP and General Counsel |